Cellectis S.A. (ALCLS.PA)
EUR 1.45
(4.01%)
EUR 1.45
(4.01%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 85.05 Million USD | 2.66% |
| 2022 | 82.84 Million USD | -18.97% |
| 2021 | 102.23 Million USD | -8.14% |
| 2020 | 111.29 Million USD | 133.78% |
| 2019 | 47.6 Million USD | 3423.83% |
| 2018 | 1.35 Million USD | 3873.53% |
| 2017 | 34 Thousand USD | -98.06% |
| 2016 | 1.75 Million USD | -19.2% |
| 2015 | 2.17 Million USD | -51.53% |
| 2014 | 4.48 Million USD | -20.17% |
| 2013 | 5.61 Million USD | -1.06% |
| 2012 | 5.67 Million USD | -91.79% |
| 2011 | 69.08 Million USD | 3694.27% |
| 2010 | 1.82 Million USD | -30.41% |
| 2009 | 2.61 Million USD | 44.12% |
| 2008 | 1.81 Million USD | 0.0% |
| 2007 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 91.22 Million USD | -3.17% |
| 2024 Q1 | 94.21 Million USD | 10.77% |
| 2023 Q4 | 85.05 Million USD | 1.32% |
| 2023 Q2 | 99.88 Million USD | 34.77% |
| 2023 FY | 85.05 Million USD | 2.66% |
| 2023 Q3 | 83.95 Million USD | -15.95% |
| 2023 Q1 | 74.11 Million USD | -10.54% |
| 2022 Q3 | 96.64 Million USD | 2.86% |
| 2022 Q4 | 82.84 Million USD | -14.27% |
| 2022 FY | 82.84 Million USD | -18.97% |
| 2022 Q2 | 93.95 Million USD | -4.85% |
| 2022 Q1 | 98.74 Million USD | -3.42% |
| 2021 Q3 | 103.28 Million USD | -2.18% |
| 2021 Q4 | 102.23 Million USD | -1.02% |
| 2021 FY | 102.23 Million USD | -8.14% |
| 2021 Q1 | 103.7 Million USD | -6.82% |
| 2021 Q2 | 105.59 Million USD | 1.82% |
| 2020 Q3 | 103.16 Million USD | 37.03% |
| 2020 FY | 111.29 Million USD | 133.78% |
| 2020 Q4 | 111.29 Million USD | 7.89% |
| 2020 Q1 | 50.04 Million USD | 5.11% |
| 2020 Q2 | 75.28 Million USD | 50.44% |
| 2019 Q2 | 47.81 Million USD | 34.13% |
| 2019 Q4 | 47.6 Million USD | 0.31% |
| 2019 FY | 47.6 Million USD | 3423.83% |
| 2019 Q3 | 47.46 Million USD | -0.74% |
| 2019 Q1 | 35.64 Million USD | 2538.64% |
| 2018 Q1 | 347 Thousand USD | 920.59% |
| 2018 Q4 | 1.35 Million USD | 177.98% |
| 2018 Q3 | 486 Thousand USD | -51.55% |
| 2018 Q2 | 1 Million USD | 189.05% |
| 2018 FY | 1.35 Million USD | 3873.53% |
| 2017 Q3 | 46 Thousand USD | -49.1% |
| 2017 Q2 | 90.37 Thousand USD | -78.86% |
| 2017 Q1 | 427.44 Thousand USD | -75.65% |
| 2017 FY | 34 Thousand USD | -98.06% |
| 2017 Q4 | 34 Thousand USD | -26.09% |
| 2016 FY | 1.75 Million USD | -19.2% |
| 2016 Q4 | 1.75 Million USD | -20.13% |
| 2016 Q2 | 2.45 Million USD | 11.23% |
| 2016 Q3 | 2.19 Million USD | -10.64% |
| 2016 Q1 | 2.21 Million USD | 1.78% |
| 2015 Q4 | 2.17 Million USD | -36.8% |
| 2015 FY | 2.17 Million USD | -51.53% |
| 2015 Q3 | 3.43 Million USD | -1.9% |
| 2015 Q2 | 3.5 Million USD | 517.73% |
| 2015 Q1 | 567.22 Thousand USD | -87.35% |
| 2014 Q1 | 4.93 Million USD | -12.05% |
| 2014 FY | 4.48 Million USD | -20.17% |
| 2014 Q4 | 4.48 Million USD | 3.84% |
| 2014 Q3 | 4.31 Million USD | -20.99% |
| 2014 Q2 | 5.46 Million USD | 10.62% |
| 2013 Q3 | 4.77 Million USD | 277.28% |
| 2013 Q4 | 5.61 Million USD | 17.68% |
| 2013 FY | 5.61 Million USD | -1.06% |
| 2013 Q2 | 1.26 Million USD | -74.56% |
| 2013 Q1 | 4.97 Million USD | -12.39% |
| 2012 FY | 5.67 Million USD | -91.79% |
| 2012 Q3 | - USD | -100.0% |
| 2012 Q4 | 5.67 Million USD | 0.0% |
| 2012 Q2 | 5.49 Million USD | 0.0% |
| 2011 Q4 | 69.08 Million USD | 0.0% |
| 2011 FY | 69.08 Million USD | 3694.27% |
| 2010 Q4 | 1.82 Million USD | 0.0% |
| 2010 FY | 1.82 Million USD | -30.41% |
| 2010 Q2 | - USD | 0.0% |
| 2009 Q4 | 2.61 Million USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 FY | 2.61 Million USD | 44.12% |
| 2008 FY | 1.81 Million USD | 0.0% |
| 2008 Q4 | 1.81 Million USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | -2409.027% |
| ABIVAX Société Anonyme | 55.46 Million EUR | -53.354% |
| Adocia SA | 13.08 Million EUR | -549.878% |
| Aelis Farma SA | 4.03 Million EUR | -2006.389% |
| Biophytis S.A. | 8.27 Million EUR | -928.489% |
| Advicenne S.A. | 17.42 Million EUR | -388.126% |
| genOway Société anonyme | 7.23 Million EUR | -1075.878% |
| IntegraGen SA | 1.12 Million EUR | -7462.315% |
| Medesis Pharma S.A. | 1.2 Million EUR | -6988.0% |
| Neovacs S.A. | 650 Thousand EUR | -12985.538% |
| NFL Biosciences SA | 62.17 Thousand EUR | -136703.165% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -1852.389% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | -3030.697% |
| Sensorion SA | 2.86 Million EUR | -2864.877% |
| Theranexus Société Anonyme | 3.64 Million EUR | -2234.766% |
| TME Pharma N.V. | 1.16 Million EUR | -7194.683% |
| Valbiotis SA | 6.87 Million EUR | -1136.639% |
| TheraVet SA | 1.15 Million EUR | -7233.255% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | -845.277% |
| DBV Technologies S.A. | 13.01 Million USD | -553.342% |
| Genfit S.A. | 70.17 Million EUR | -21.2% |
| GeNeuro SA | 7.73 Million EUR | -999.227% |
| Innate Pharma S.A. | 39.89 Million EUR | -113.21% |
| Inventiva S.A. | 37.4 Million EUR | -127.38% |
| MaaT Pharma SA | 14.07 Million EUR | -504.306% |
| MedinCell S.A. | 58.96 Million EUR | -44.258% |
| Nanobiotix S.A. | 50.56 Million EUR | -68.211% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | -85.708% |
| Poxel S.A. | 46.9 Million EUR | -81.356% |
| GenSight Biologics S.A. | 18.42 Million EUR | -361.558% |
| Transgene SA | 1.25 Million EUR | -6666.587% |
| Valneva SE | 208.81 Million EUR | 59.267% |